Supersaturated Oxygen (SSO2) Therapy in STEMI Treatments
Published: 06 December 2021
Part 3 | Session 2 Overview of the Problem: Microvascular Obstruction and Infarct Size in STEMI
Part 3 | Session 3 Questions and Answers
Part 2 | Session 1 Current State of STEMI Care Dan Burkhoff, Steven Yakubov, Andreas Schäfer, Richard Schatz
Part 2 | Session 2 Evolution of STEMI Treatment Dan Burkhoff, Richard Schatz, Steven Yakubov, Andreas Schäfer
Part 2 | Session 3 SSO2 Mechanism of Action Richard Schatz, Dan Burkhoff, Steven Yakubov, Andreas Schäfer
Part 2 | Session 4 Clinical Results of SSO2 Therapy with Case Presentation Steven Yakubov, Dan Burkhoff, Andreas Schäfer, Richard Schatz
Part 2 | Session 5 Case Presentation by Dr A Schäfer Andreas Schäfer, Dan Burkhoff, Steven Yakubov, Richard Schatz
Despite advances in reperfusion with primary stenting, progress in STEMI outcomes has stalled over the past 20 years. With 90% of coronary blood flow in the capillaries, the answer might be in the microvasculature. TherOx SSO2 Therapy is the first FDA approved therapy shown to significantly reduce the infarct size in STEMI patients.
During this series of webinars on Supersaturated Oxygen (SSO2) Therapy, our faculty of renowned international experts will discuss and dissect the mechanisms and data around this promising new therapy for STEMI patients.
- Understand how SSO2 Therapy works
- Hear about trends in STEMI treatment
- Explore the role of microvascular obstruction and infarct size in outcomes
- Understand the science behind SSO2 Therapy
This series is designed for the entire cardiology community:
- Interventional Cardiologists
- Clinical Fellows and Trainees
More from this programme
Supersaturated Oxygen Therapy (SSO2): The Next Frontier in STEMI Treatment
SSO2 Therapy in STEMI to Reduce Infarct Size: A Conversation with Global Thought Leaders
Infarct Size, Microvascular Obstruction and Outcomes in STEMI: An Expert Panel Discussion
Assistant Professor and Interventional Cardiologist
Dr Nadia Sutton is an Assistant Professor, interventional cardiologist and vascular biologist in the Division of Cardiovascular Medicine and the Frankel Cardiovascular Center at University of Michigan, Michigan, US.